tradingkey.logo
tradingkey.logo
Buscar

AxoGen Inc

AXGN
Añadir a la lista de seguimiento
44.020USD
-2.170-4.70%
Cierre 07/01, 16:00ETCotizaciones retrasadas 15 min
2.08BCap. mercado
PérdidaP/E TTM

Más Datos de AxoGen Inc Compañía

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

Información de AxoGen Inc

Símbolo de cotizaciónAXGN
Nombre de la empresaAxoGen Inc
Fecha de salida a bolsaDec 17, 1986
Director ejecutivoDale (Michael Donald)
Número de empleados451
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 17
Dirección13631 Progress Blvd.
CiudadALACHUA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal32615
Teléfono13864626817
Sitio Webhttps://www.axogeninc.com/
Símbolo de cotizaciónAXGN
Fecha de salida a bolsaDec 17, 1986
Director ejecutivoDale (Michael Donald)

Ejecutivos de AxoGen Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--
Mr. John H. Johnson
Mr. John H. Johnson
Independent Director
Independent Director
--
--
Mr. William P. (Bill) Burke
Mr. William P. (Bill) Burke
Independent Director
Independent Director
--
--
Dr. Joseph (Adrian) Tyndall, M.D.
Dr. Joseph (Adrian) Tyndall, M.D.
Independent Director
Independent Director
--
--
Mr. Marc A. Began
Mr. Marc A. Began
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lindsey Hartley
Ms. Lindsey Hartley
Chief Financial Officer
Chief Financial Officer
65.15K
+6.77%
Mr. Jens Schroeder Kemp
Mr. Jens Schroeder Kemp
Chief Marketing Officer
Chief Marketing Officer
64.95K
-6.16%
Mr. Paul G. Thomas
Mr. Paul G. Thomas
Independent Chairman of the Board
Independent Chairman of the Board
28.93K
+65.23%
Mr. Erick Wayne Devinney
Mr. Erick Wayne Devinney
Chief Innovation Officer
Chief Innovation Officer
--
--
Ms. Amy A. Mcbride-Wendell
Ms. Amy A. Mcbride-Wendell
Lead Independent Director
Lead Independent Director
--
--
Mr. Alan M. Levine
Mr. Alan M. Levine
Independent Director
Independent Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de AxoGen Inc?

Los cinco principales accionistas de AxoGen Inc son: Ms. Lindsey Hartley

¿Cuántas instituciones poseen acciones de AxoGen Inc (AXGN)?

A fecha de 2026Q1, 399 instituciones poseen acciones de AxoGen Inc, con un valor de mercado combinado de aproximadamente 48.71M, lo que representa el 91.60% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 3148593.00.